Rare diseases
Expansion into new international biotech markets can be challenging. Unfamiliar regulations and licensing, coupled with language and cultural differences, can all be barriers to growth. If you’re considering venturing into Europe and beyond, our easy-to-follow guides, shaped by 30 years of expertise in the rare disease market, will assist you in navigating challenges and gaining a profound understanding of the complexities involved in launching orphan drugs into new markets.
Thought Leadership
Take the risk out of your orphan drug distribution in Europe
Thought Leadership
EU orphan drug roll out: navigating regulatory challenges
Thought Leadership
Integrating clinical studies and Patient Support Programs(PSPs) for holistic rare disease care
Thought Leadership
Enabling early access to rare and orphan drugs in Europe